Showing 11-20 of 326 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| A Novel Ultra-Rapid Insulin | Wayne State University | Zhiqiang Cao | Improving Lives | 01-November-2025 to 31-October-2026 | $299,994.92 |
| Assess the antigenic profile in human T1D: from β-cell crinophagy to peripheral blood | Washington University | Xiaoxiao Wan | Cures | 01-April-2022 to 31-March-2027 | $750,000.00 |
| Genetic Engineering to Improve Engraftment of Stem Cell-Derived Islets | Washington University | Jeffrey Millman | Cures | 01-February-2023 to 31-January-2026 | $450,000.00 |
| Enhancing Human Stem Cell-Derived Islet Survival and Function Using SA-PD-L1-Presenting Microgels | Washington University | Jeffrey Millman | Cures | 01-August-2024 to 31-July-2027 | $1,125,000.00 |
| Ketone Monitoring in T1D: Effect of SGLT2i during Usual Care and with Insulin Deficiency | Washington University | Janet McGill | Improving Lives | 01-September-2022 to 31-August-2025 | $332,804.10 |
| Combining Arteriovenous Bundle and ECM-Based Biomaterial Technologies to Induce Potent Neovascularization Following Islet Transplantation | Wake Forest University Health Sciences | Giuseppe Orlando | Cures | 01-April-2025 to 31-March-2026 | $248,692.00 |
| Developing Fit-For-Purpose Patient-reported Outcomes (PRO) Measure(s) in Type 1 Diabetes | Vector Psychometric Group | R. J. Wirth | Cures | 01-February-2025 to 31-March-2027 | $797,087.00 |
| Targeting the Autoimmune Germinal Center Axis in Type 1 Diabetes | Vanderbilt University Medical Center (VUMC) | Rachel Bonami | Cures | 01-September-2023 to 31-August-2025 | $594,198.02 |
| Investigation of AKS-107 immunotherapeutic in mice and human cells | Vanderbilt University Medical Center (VUMC) | Rachel Bonami | Cures | 01-July-2024 to 30-June-2027 | $800,000.00 |
| Targeting the Opposing Roles of Prostaglandin E2 Receptors, EP3 and EP4, in the Pathogenesis of Type One Diabetes | Vanderbilt University Medical Center (VUMC) | Maureen Gannon | Cures | 01-October-2023 to 31-March-2026 | $200,000.00 |